Literature DB >> 3161808

Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system.

Y Hitomi, N Ikari, S Fujii.   

Abstract

The inhibitory effects of 6-amidino-2-naphthyl-4-guanidinobenzoate X dimethanesulfonate (FUT-175) on the human Hageman factor fragment (HFf), factor Xa, thrombin, plasma kallikrein, and plasmin were studied. FUT-175 inhibited plasma kallikrein most (IC50 = 3.0 X 10(-9) M), followed by HFf (IC50 = 3.3 X 10(-7) M). FUT-175 was found to have an anticoagulant effect in the APTT and PT assay systems of human plasma. The concentration of FUT-175 for twofold increase in the clotting time in the APTT assay system was 5 X 10(-7) M.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3161808     DOI： 10.1159/000215139

Source DB:  PubMed          Journal:  Haemostasis        ISSN： 0301-0147


  16 in total

1.  Immunoadsorbent plasmapheresis for a patient with antiphospholipid syndrome during pregnancy.

Authors:  S Kobayashi; N Tamura; H Tsuda; C Mokuno; H Hashimoto; S Hirose
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

2.  Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation.

Authors:  Sang Jin Han; Hyoung Soo Kim; Kun Il Kim; Sung Mi Whang; Kyung Soon Hong; Won Ki Lee; Sun Hee Lee
Journal:  J Korean Med Sci       Date:  2011-06-20       Impact factor: 2.153

3.  Effect of nafamostat mesilate on Na+ and K+ transport properties in the rabbit cortical collecting duct.

Authors:  S Muto; M Imai; Y Asano
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

4.  Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation.

Authors:  M Murakawa; T Okamura; T Shibuya; M Harada; T Otsuka; Y Niho
Journal:  Ann Hematol       Date:  1992-05       Impact factor: 3.673

5.  Structure, function, and pharmacology of acid-sensing ion channels (ASICs): focus on ASIC1a.

Authors:  Stefan Gründer; Xuanmao Chen
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2010-03-18

6.  Pretreatment with nafamostat mesilate, a kallikrein inhibitor, to decrease withdrawal response associated with rocuronium.

Authors:  Yoon Hee Kim; Young Kwon Go; Jung Un Lee; Woo Suk Chung; Yong Sup Shin; Kyu Cheol Han; Ji Eun Shin; Suk Hoon Lee
Journal:  J Anesth       Date:  2010-05-25       Impact factor: 2.078

7.  Aggressive early surgical strategy in patients with intracranial hemorrhage: a new cardiopulmonary bypass option.

Authors:  Takahiro Yamazato; Noriko Oyama; Takayuki Fujii; Noriyuki Abe; Yuta Ikemiya; Hiroshi Munakata
Journal:  Gen Thorac Cardiovasc Surg       Date:  2021-11-23

8.  Mechanisms of the hyperkalaemia caused by nafamostat mesilate: effects of its two metabolites on Na+ and K+ transport properties in the rabbit cortical collecting duct.

Authors:  S Muto; M Imai; Y Asano
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

9.  The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation.

Authors:  Jae Ha Lee; Jin Han Park; Ji Hoon Jang; Se Hun Kim; Sung Yong Hong; Woon Heo; Dong-Hwan Lee; Hye Sook Choi; Ki Hoon Kim; Hang-Jea Jang
Journal:  Acute Crit Care       Date:  2022-04-20

10.  Nafamostat mesilate: can it be used as a conduit preserving agent in coronary artery bypass surgery?

Authors:  Yoo Sang Yoon; Hyunkong Oh; Yonghwan Kim; Seung Pyung Lim; Cuk-Seong Kim; Min-Woong Kang
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2013-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.